Philadelphia Pharmaceuticals Company (ASE:PHIL)

Market Cap	11.63M +13.1%
Revenue (ttm)	9.17M +4.6%
Net Income	1.01M +22.4%
EPS	0.13 +22.4%
Shares Out	7.50M
PE Ratio	11.57
Forward PE	n/a
Dividend	0.07 (4.52%)
Ex-Dividend Date	Mar 30, 2026

Volume	131
Average Volume	286
Open	1.550
Previous Close	1.590
Day's Range	1.550 - 1.550
52-Week Range	1.360 - 1.700
Beta	-0.07
RSI	51.20
Earnings Date	Apr 23, 2026

About ASE:PHIL

Philadelphia Pharmaceuticals Company develops, manufactures, and markets human pharmaceutical products, cosmetics, and medical devices of various therapeutic categories in Jordan. The company provides products for skin related disorders, including anti-lice and scabicides preparations, antiseptics and disinfectants, bleaching and hyperpigmentation disorders preparations, emollients and protectives, keratolytics/topical psoriasis treatment preparations, and skin healing agents, as well as agents for dermatitis; and topical acne preparation, anti...

• Industry: Pharmaceutical Preparations
• Founded: 1993
• Employees: 129
• Stock Exchange: Amman Stock Exchange
• Ticker Symbol: PHIL

Financial Performance

In 2025, ASE:PHIL's revenue was 9.17 million, an increase of 4.64% compared to the previous year's 8.76 million. Earnings were 1.01 million, an increase of 22.35%.